Celgene management restructuring

02 Jan 2006
News

Executive Summary

Celgene Chairman and CEO John Jackson will step down as CEO effective May 1, 2006, but will continue serving as chairman of the board of directors. President and COO Sol Barer will assume the position of CEO, while senior VP and CFO Robert Hugin will take over Barer's current role. The biopharmaceutical company said it is actively seeking a new CFO and hopes to fill the position by May. The new management team will be responsible for overseeing the launch of Revlimid; the transition announcement coincided with FDA approval of Revlimid (lenalidomide) Dec. 27 for the treatment of blood cancer...

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS046698

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS046698

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Celgene management restructuring

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert